Cargando…

XRT-01. LONG-TERM HEARING LOSS IN CHILDREN WITH MEDULLOBLASTOMA AFTER PROTON IRRADIATION AND CHEMOTHERAPY

PURPOSE: To evaluate the incidence and risk factors for hearing loss (HL) among children with medulloblastoma treated with proton irradiation and cisplatin. METHODS: We identified children with medulloblastoma ≥3 years of age treated at Texas Children’s Hospital between 2007-2022. Audiograms were gr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abu-Arja, Mohammad H, Brown, Austin L, Su, Jack M, Okcu, M Fatih, Lindsay, Holly B, McGovern, Susan L, McAleer, Mary Frances, Grosshans, David R, Chintagumpala, Murali M, Paulino, Arnold C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: Radiation Oncology - XRT
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259931/ http://dx.doi.org/10.1093/neuonc/noad073.297

Ejemplares similares

XRT-07. LATE-ONSET LYMPHOPENIA DURING CRANIOSPINAL RADIATION IS ASSOCIATED WITH AN INCREASED RISK OF TUMOR RECURRENCE IN NEWLY-DIAGNOSED PEDIATRIC MEDULLOBLASTOMA
por: Lindsay, Holly, et al.
Publicado: (2023)

XRT-04. THE ROLE OF STEREOTACTIC RADIOSURGERY FOR MENINGIOMAS IN PEDIATRIC PATIENTS
por: Shanahan, Regan, et al.
Publicado: (2023)

XRT-03. EFFICACY OF RE-IRRADIATION FOR PEDIATRIC DIFFUSE INTRINSIC PONTINE GLIOMAS
por: Cai, Linbo, et al.
Publicado: (2023)

XRT-06. RAPID PTEFB-DEPENDENT TRANSCRIPTIONAL REORGANIZATION UNDERPINS THE GLIOMA ADAPTIVE RESPONSE TO RADIOTHERAPY
por: Walker, Faye, et al.
Publicado: (2023)

XRT-05. LITHIUM PREVENTS RADIATION-INDUCED HIPPOCAMPAL MICROGLIA SENESCENCE IN A MOUSE MODEL OF PEDIATRIC CRANIAL RADIOTHERAPY
por: Rodrigues, Carlos, et al.
Publicado: (2023)

XRT-02. SINGLE-CELL RNA SEQUENCING IDENTIFIES FUNCTIONAL MACROPHAGE SUBSETS THAT ARE ENRICHED IN RESPONSE TO DIFFERENTIAL PHAGOCYTOSIS INDUCTION AGAINST GLIOMA
por: Lakshmanachetty, Senthilnath, et al.
Publicado: (2023)

MBCL-35. SALVAGE RADIATION THERAPY FOR PROGRESSIVE AND/OR RELAPSED PEDIATRIC MEDULLOBLASTOMA
por: Baig, Muhammad, et al.
Publicado: (2020)

HGG-22. PROGNOSTIC FACTORS FOR PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH NON-DIPG GRADE 4 GLIOMAS: A CONTEMPORARY POOLED INSTITUTIONAL EXPERIENCE
por: Matsui, Jennifer, et al.
Publicado: (2023)

PAEDIATRIC-01 SURGICAL OUTCOME OF MEDULLOBLASTOMA IN ETHIOPIA
por: Akililu, Yemisirach Bizuneh, et al.
Publicado: (2023)

LGG-24. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR MANAGEMENT AND OUTCOME: A SINGLE CENTER EXPERIENCE
por: Munir, Faryal, et al.
Publicado: (2023)

Outcomes for pediatric patients with central nervous system germ cell tumors treated with proton therapy
por: Greenfield, Brad J., et al.
Publicado: (2016)

MDB-01. ELUCIDATING THE ROLE OF THE BAIAP2-CDC42 INTERACTION MEDULLOBLASTOMA
por: Ruiz, Luz, et al.
Publicado: (2023)

RONC-09. PSEUDOPROGRESSION AFTER PROTON THERAPY OF PEDIATRIC SPINAL PILOCYTIC ASTROCYTOMA AND MYXOPAPILLARY EPENDYMOMA
por: McGovern, Susan, et al.
Publicado: (2020)

QOL-28. NEUROCOGNITIVE PROFILE OF PEDIATRIC MEDULLOBLASTOMA PATIENTS PRIOR TO RADIATION THERAPY
por: Baig, Muhammad, et al.
Publicado: (2020)

Referral Patterns and Treatment Delays in Medulloblastoma: A Large Academic Proton Center Experience
por: Liu, Sean M., et al.
Publicado: (2020)

RONC-05. PRESERVING VISION IN OPTIC PATHWAY GLIOMA AMONG PATIENTS WITHOUT NEUROFIBROMATOSIS TYPE 1
por: Hanania, Alexander, et al.
Publicado: (2020)

RONC-06. Stereotactic radiosurgery and stereotactic radiotherapy for pediatric brain metastases or recurrences
por: McGovern, Susan, et al.
Publicado: (2022)

QOL-01. LONGITUDINAL COMPARISON OF NEUROCOGNITIVE TRAJECTORIES IN PEDIATRIC MEDULLOBLASTOMA PATIENTS TREATED WITH PROTON VERSUS PHOTON RADIOTHERAPY
por: Kahalley, Lisa, et al.
Publicado: (2020)

NEIM-01 IMMUNOSUPPRESSION IN THE GLIOMA MICROENVIRONMENT: USING PET IMAGING TO HIGHLIGHT THE PRESENCE OF TIGIT
por: Frederico, Stephen, et al.
Publicado: (2023)

Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy
por: Moeller, Benjamin J, et al.
Publicado: (2011)

MENINGIOMA-01 HISTOPATHOLOGICAL PATTERN OF MENINGIOMA IN IBADAN, SOUTHWEST NIGERIA: A 15-YEAR RETROSPECTIVE STUDY
por: Ogunsanya, Temitope
Publicado: (2023)

GLIOMA-01 GENETIC INVESTIGATIONS AND COUNSELING IN FAMILIAL MSS TURCOT SYNDROME ASSOCIATED TO INFERTILITY AND CHILD MORTALITY
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2023)

OTHER-01 INTERNATIONAL CLASSIFICATION, BRAIN TUMOURS AND CARE: ACCOUNTING FOR THE DIAGNOSTIC POTENTIAL OF SUB-SAHARAN AFRICA
por: Llewellyn, Henry
Publicado: (2023)

METASTASES-01 OUTCOME OF BRAIN METASTASES TREATED WITH GAMMA KNIFE STEREOTACTIC RADIOSURGERY (GKSR): COHORT RETROSPECTIVE STUDY ON 205 CASES
por: Bankole, Nourou Dine Adeniran, et al.
Publicado: (2023)

MDB-42. UNCOVERING DYNAMIC CHANGES IN MEDULLOBLASTOMA ASSOCIATED VASCULATURE IN ZEBRAFISH
por: Morris, Elysse, et al.
Publicado: (2023)

MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2023)

MDB-28. DEEP LEARNING-BASED PERSONALIZED SURVIVAL PREDICTION FOR MEDULLOBLASTOMA
por: Stefan, Sabina, et al.
Publicado: (2023)

MDB-40. TRANSCRIPTOME-BASED DRUG REPURPOSING IN GROUP 3 MEDULLOBLASTOMA
por: Doss, David, et al.
Publicado: (2023)

MDB-11. AN ONLINE CALCULATOR USING MACHINE LEARNING FOR PREDICTION OF SURVIVAL IN PEDIATRIC PATIENTS WITH MEDULLOBLASTOMA
por: Kuo, Cathleen, et al.
Publicado: (2023)

MDB-38. COMPUTATIONAL DRUG SENSITIVITY PREDICTS MEDULLOBLASTOMA SUBGROUP-SPECIFIC THERAPEUTICS
por: Jermakowicz, Anna, et al.
Publicado: (2023)

MDB-41. TARGETING EPIGENETIC REGULATORS TO INHIBIT GROUP 3 MEDULLOBLASTOMA MIGRATION
por: Jangde, Nitish, et al.
Publicado: (2023)

MDB-29. MEDULLOBLASTOMA SUBGROUP-SPECIFIC CHROMATIN STATES REVEAL NOVEL THERAPEUTIC VULNERABILITIES
por: Tao, Ran, et al.
Publicado: (2023)

MDB-17. THE PTBP2 SPLICING FACTOR IS ESSENTIAL IN GROUP 3/4 MEDULLOBLASTOMA
por: Caisova, Veronika, et al.
Publicado: (2023)

MDB-35. RECURRENT MEDULLOBLASTOMA A RARE COMPLETE RESPONSE IN EXTRA NEURAL DISEASE
por: Schwartz, Jonathan, et al.
Publicado: (2023)

MDB-15. CLINICAL CHARACTERISTICS AND OUTCOME OF CHILDHOOD LI-FRAUMENI SYNDROME MEDULLOBLASTOMA PATIENTS
por: Kolodziejczak, Anna, et al.
Publicado: (2023)

MDB-09. IMPACT OF PRDM6 ON CHROMATIN ACCESSIBILITY, GENE EXPRESSION, AND MEDULLOBLASTOMA FORMATION
por: Schmidt, Christin, et al.
Publicado: (2023)

MDB-10. EPIDEMIOLOGICAL PROFILE OF MEDULLOBLASTOMA IN MOROCCO: A 2-YEAR RETROSPECTIVE STUDY
por: Erefai, Ouassima, et al.
Publicado: (2023)

MDB-05. HUMAN FETAL CEREBELLAR CELL ATLAS INFORMS MEDULLOBLASTOMA ORIGIN AND ONCOGENESIS
por: Luo, Zaili, et al.
Publicado: (2023)

MDB-19. MULTIOMIC PROFILING OF MEDULLOBLASTOMA REVEALS SUBTYPE-SPECIFIC TARGETABLE ALTERATIONS AT THE PROTEOME AND N-GLYCAN LEVEL
por: Godbole, Shweta, et al.
Publicado: (2023)

ATRT-19. RARE EMBRYONAL TUMORS INCLUDING EMBRYONAL TUMOR MULTILAYER ROSETTE, OUTCOME AND PATTERN OF TREATMENT FAILURE: MD ANDERSON CANCER CENTER EXPERIENCE
por: He, Jiasen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a440aspjamgb9g5r23mrpb941c